Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ARX517
ARX517
ESMO: Ambrx's 'reset' arrives at the last line of prostate cancer, offering the kind of safety rarely seen
Fierce Biotech
Mon, 10/23/23 - 10:33 am
ESMO
Ambrx
prostate cancer
ARX517
antibody-drug conjugate